Abstracts Archive - Page 1068 of 2607 - ACR Meeting Abstracts

Abstract Number: 1918 • 2019 ACR/ARP Annual Meeting
Urine CD163 Significantly Discriminates Active Lupus Nephritis and Strongly Correlates with Proliferative Glomerulonephritis
Ting Zhang¹, Ramesh Saxena ², Chi Chiu Mok ³, Michelle Petri ⁴ and Chandra Mohan ⁵, ¹Biomedical Engineering, University of Houston, Houston, TX, ²UTSW, Dallas, ³Department of Medicine, Tuen Mun Hospital, Hong Kong, China (People's Republic), ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵University of Houston, Houston
Background/Purpose: CD163 is a marker for alternatively activated M2 macrophages, which have been implicated in the pathogenesis of lupus nephritis (LN). The potential of urine…
Abstract Number: 1919 • 2019 ACR/ARP Annual Meeting
Development of a Multi-Modality Imaging Approach to Evaluate Lupus Nephritis
Amit Saxena ¹, David Karp ², Brad Rovin ³, Mikael Boesen ⁴, Olga Kubassova ⁵, Claire Dykas ⁶, Anthony Yeo ⁷ and Peter Lipsky⁸, ¹New York University School of Medicine, New York, NY, ²UTSouthwestern Medical Center, Dallas, TX, ³The Ohio State University Medical Center, Columbus, OH, ⁴Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ⁵Image Analysis Group, London, United Kingdom, ⁶AmpelBioSolutions, Charlottesville, VA, ⁷RILITE Research Institute, Charlottesville, VA, ⁸AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Lupus nephritis (LN) remains a significant cause of morbidity and mortality in subjects with Systemic Lupus Erythematosus (SLE). The gold standard for evaluation of…
Abstract Number: 1920 • 2019 ACR/ARP Annual Meeting
School Nurse Education for Juvenile Idiopathic Arthritis
W. Blaine Lapin¹, Carleigh Kutac ², Danielle Guttman-Lapin ³, Amanda Brown ², Eyal Muscal ² and Filiz Seeborg ², ¹Baylor College of Medicine, Connecticut Children's Medical Center, Houston, TX, ²Baylor College of Medicine, Houston, TX, ³Aldine Independent School District, Houston, TX
Background/Purpose: There is a paucity of literature on the challenges children with JIA face at school. Despite treatment advances, children with JIA often rate their…
Abstract Number: 1921 • 2019 ACR/ARP Annual Meeting
Parent-Reported Medication Side-Effects and Their Impact on Health-Related Quality of Life in Children with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry
Gaëlle Chédeville¹, Michelle Batthish ², Roberta Berard ³, Roxana Bolaria ⁴, Alessandra Bruns ⁵, David Cabral ⁶, Ciaran Duffy ⁷, Kerstin Gerhold ⁸, Tommy Gerschman ⁶, Jean-Philippe Proulx-Gauthier ⁹, Alan Rosenberg ¹⁰, Dax Rumsey ¹¹, Heinrike Schmeling ¹², Natalie Shiff ¹³, Gordon Soon ¹⁴, Lori Tucker ¹⁵ and Jaime Guzman ⁶, ¹The Montreal Children's Hospital, McGill University, Montreal, Canada, ²McMaster University, Hamilton, Canada, ³Children's Hospital, London Health Sciences Centre, London, Canada, ⁴University of British Columbia, Victoria, BC, Canada, ⁵Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of British Columbia, Vancouver, BC, Canada, ⁷University of Ottawa, Ottawa, ON, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Université Laval, Québec, QC, Canada, ¹⁰University of Saskatchewan, Saskatoon, SK, Canada, ¹¹University of Alberta, Edmonton, AB, Canada, ¹²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹³University of Florida, Gainesville, FL, ¹⁴University of Toronto, Toronto, ON, Canada, ¹⁵British Columbia Children’s Hospital, Vancouver, Canada
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children and many medications are available to control the disease. While physician-reported adverse…
Abstract Number: 1922 • 2019 ACR/ARP Annual Meeting
Improvement in Hepatitis B Screening Prior to Initiation of Biologic Therapy in the Pediatric Rheumatology Clinic
Vidya Sivaraman¹, Kelly Wise ², Elizabeth Bley ³, M. Zachary Dawson ⁴, Jennifer DeSalvo ³, Samuel Lazaroff ⁵, Michael Neiger ³, Elizabeth Shisler ⁴, Stephanie Lemle ² and Monica Ardura ², ¹Nationwide Children's Hospital and The Ohio State University, Columbus, OH, ²Nationwide Children's Hospital, Columbus, OH, ³The Ohio State University, Columbus, OH, ⁴Rainbow Babies and Children's Hospital, Cleveland, OH, ⁵Vanderbilt University, Nashville, TN
Background/Purpose: Use of certain biologic medications increases the risk of reactivation of hepatitis B. Therefore, screening for hepatitis B viral (HBV) infection is recommended prior…
Abstract Number: 1923 • 2019 ACR/ARP Annual Meeting
Disability and Health-Related Quality of Life Outcomes in Patients with Systemic or Polyarticular Juvenile Idiopathic Arthritis Treated with Tocilizumab in Randomized Controlled Phase 3 Trials
Hermine Brunner¹, Chen Chen ¹, Alberto Martini ², Graciela Espada ², Rik Joos ², Jonathan Akikusa ², Jeffrey Chaitow ², Maria Luz Gámir Gámir ², Yukiko Kimura ³, Christoph Rietschel ², Daniel Siri ², Elzbieta Smolewska ², Heinrike Schmeling ¹, Diane Brown ¹, Fabrizio De Benedetti ⁴, Daniel J. Lovell ⁵, Bin Huang ¹ and Nicolino Ruperto ², ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ³Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Cincinnati, OH, ⁴Bambino Gesù Children’s Hospital, Rome, Italy, ⁵Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati
Background/Purpose: Tocilizumab (TCZ) was approved for the treatment of systemic juvenile idiopathic arthritis (sJIA) and polyarticular juvenile idiopathic arthritis (pJIA) based on the results of…
Abstract Number: 1924 • 2019 ACR/ARP Annual Meeting
Assessing Psychosocial Needs in Juvenile Dermatomyositis Patients Across the United Kingdom
Polly Livermore¹ and Lucy Wedderburn ², ¹ICH/UCL, Arlesey, United Kingdom, ²ICH/UCL, London, United Kingdom
Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare, autoimmune inflammatory condition primarily affecting the muscles and skin. With a mean age of onset of 7 years…
Abstract Number: 1925 • 2019 ACR/ARP Annual Meeting
Discriminant and Predictive Ability of the Parent Version of the Juvenile Arthritis Disease Activity Score in Two Large Multination Cohorts of Patients with Juvenile Idiopathic Arthritis
Francesca Ridella ¹, Giedre Januskeviciute ², Chiara Trincianti ³, Evert Hendrik Pieter Van Dijkhuizen ⁴, Gabriella Giancane ⁵, Serena Pastore ⁶, Kirsten Minden ⁷, Maria Ekelund ⁸, Patrizia Barone ⁹, Matilda Laday ¹⁰, Nicolino Ruperto ¹¹, Angelo Ravelli ¹² and Alessandro Consolaro¹³, ¹Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy, Genova, Italy, ²Klaipeda Children's Hospital, Klaipeda, Lithuania, Klaipeda, Lithuania, ³Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy, Genoa, Italy, ⁴Wilhelmina Children’s Hospital, Department of Pediatric Immunology and Rheumatology, Utrecht, The Netherlands, Utrecht, Netherlands, ⁵Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genoa, Italy, ⁶Institute for Maternal and Child Health IRCCS "Burlo Garofolo," Trieste, Italy, Trieste, Italy, ⁷German Rheumatism Research Centre Berlin, and Charité University Medicine, Department of Rheumatology and Clinical Immunology, Berlin, Germany, Berlin, Germany, ⁸Ryhov County Hospital, Futurum - the Academy for health and care, Jonkoping, Sweden, Jonkoping, Sweden, ⁹Department of Pediatrics, University of Catania, Catania, Italy, Catania, Italy, ¹⁰Spitalul Clinic Județean De Urgenta, Tîrgu-Mures, Romania, Tîrgu-Mures, Romania, ¹¹Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ¹²IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, ¹³Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genova, Italy
Background/Purpose: The assessment of disease activity plays a pivotal role in the management of children with juvenile idiopathic arthritis (JIA). Most recent recommendations require that…
Abstract Number: 1926 • 2019 ACR/ARP Annual Meeting
Characterization of DOCK8 as a Novel Gene Associated with Macrophage Activation Syndrome
Mingce Zhang ¹, Remy Cron ², Devin Absher ³, Courtney Crayne ², Prescott Atkinson ², W. Winn Chatham ² and Randy Cron¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³HudsonAlpha Institute for Biotechnology, Huntsville, AL
Background/Purpose: Macrophage activation syndrome (MAS), also known as secondary hemophagocytic lymphohistiocytosis (HLH), is a life threatening condition that commonly presents with unremitting fever and shock…
Abstract Number: 1927 • 2019 ACR/ARP Annual Meeting
Role of Mitochondrial DNA from OA Patients in Cellular Apoptosis, Senescence and Autophagy
Mercedes Fernandez-Moreno¹, Andrea Dalmao-Fernández ², Uxia Nogueira-Recalde ³, Tamara Hermida-Gómez ⁴, Maria E Vazquez-Mosquera ⁵, Sara Relaño ⁶, Ignacio Rego-Pérez ⁶ and Francisco J. Blanco ⁶, ¹Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España. CIBER-BBM, A Coruña, Spain, ²Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Galicia, Spain, ³Grupo de Biología del Cartílago, Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña, Sergas, A Coruña, Spain, A Coruña, Spain, ⁴Unidad de Bioingeniería Tisular y Terapia Celular (GBTTC-CHUAC). Grupo de Investigación en Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC). Sergas. Centro de Investigaciones Científicas Avanzadas (CICA), A Coruña, Spain, ⁵Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, ⁶Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain
Background/Purpose: Background. With the redefinition of Osteoarthritis (OA) and the understanding that the joint behaves as an organ, OA is now considered a systemic illness…
Abstract Number: 1928 • 2019 ACR/ARP Annual Meeting
Identification of Immunological Processes Associated with the Response to Abatacept in Rheumatoid Arthritis Using Longitudinal Blood RNA-seq Analysis
Antonio Julià¹, Maria Lopez Lasanta ², Antonio Gómez ³, Irene Bonafonte ⁴, Raimon Sanmartí ⁵, Carlos Marras ⁶, José Manuel Pina ⁷, Susana Romero-Yuste ⁸, Raul Veiga ⁹, Pilar Navarro ⁹, Carmen Moragues Pastor ¹⁰, Silvia Martínez ¹¹, Francisco J. De Toro ¹², Amalia Sanchez ¹³, Dacia Cerdà ¹⁴, Alejandro Prada ¹⁵, Alba Erra ¹⁶, Jordi Monfort ¹⁷, A. Urruticoechea-Arana ¹⁸, Núria Palau ¹⁹, Raquel Lastra ²⁰, Raúl Tortosa ³, Andrea Pluma ²¹ and Sara Marsal ²², ¹Rheumatology Research Group, Vall d’Hebron Hospital Research Institute, Barcelona, Spain., Barcelona, Catalonia, Spain, ²Hospital Universitari Vall Hebrón, Barcelona, Barcelona, Catalonia, Spain, ³Hospital Vall d'Hebron, Barcelona, Barcelona, Spain, ⁴Vall Hebron Hospital Research Institute, Barcelona, Spain, ⁵Hospital Clínic, Barcelona, Barcelona, Spain, ⁶Hospital Universitario Virgen de la Arrixaca, Murcia, Murcia, Spain, ⁷Hospital de Barbastro, Huesca, Barbastro, Huesca, Spain, ⁸Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain, ⁹Hospital Universitario Fuenlabrada, Fuenlabrada, Spain, ¹⁰Platò Hospital, Barcelona, Spain, Barcelona, Spain, ¹¹Hospital Universitari Mútua Terrassa, Terrassa, Spain, ¹²University Hospital A Coruña, A Coruña, Spain, ¹³Hospital Universitario Lucus Augusti, Lugo, Lugo, Spain, ¹⁴Hospital Moisès Broggi, Sant Joan Despí, Sant Joan Despí, Spain, ¹⁵Hospital Universitario Torrejón de Ardoz, Torrejón de Ardoz, Spain, ¹⁶Hospital Sant Rafael, Barcelona, Barcelona, Spain, ¹⁷Hospital del Mar, Barcelona, Spain, ¹⁸HU Can Misses, Ibiza, Spain, ¹⁹Hospital Vall Hebrón Barcelona, Barcelona, Spain, ²⁰Hospital Vall Hebron, Barcelona, Barcelona, Spain, ²¹Hospital Universitari Vall d'Hebron, Barcelona, Spain, ²²Vall d’Hebron Hospital, Barcelona, Catalonia, Spain
Background/Purpose: Abatacept (CTLA4-Ig) is an approved biological therapy for the treatment of rheumatoid arthritis (RA). Similar to other biological agents, most patients (50-60%) respond significantly…
Abstract Number: 1929 • 2019 ACR/ARP Annual Meeting
Identification and Validation of Transcriptional Genes Associated with Osteoporotic Vertebral Fractures by Microarray Study, in Community Elderly Women
Levi Jales Neto¹, Zofia Wicik ², Georgea Torres ¹, Liliam Takayama ¹, Neusa Lopes ¹, alexandre Pereira ¹ and Rosa Pereira ³, ¹University of Sao Paulo, Sao Paulo, Brazil, ²University of Sao Paulo, São Paulo, Brazil, ³Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil
Background/Purpose: The pathogenesis of osteoporosis, a common disease with high morbidity1, comprises genetic and environmental factors2. Recent studies demonstrated that blood samples are a source…
Abstract Number: 1930 • 2019 ACR/ARP Annual Meeting
Analysis of Lupus Nephritis Gene Expression Reveals Dysregulation of Pathogenic Pathways Activated Within Infiltrating Cells
Adam Labonte¹, Jackson Xu ², Sarah Heuer ², Robert Robl ², Prathyusha Bachali ¹, Michelle Catalina ¹, Peter Lipsky ³ and Amrie Grammer ⁴, ¹AMPEL Biosolutions and the RILITE Research Institute, Charlottesville, VA, ²AMPEL BioSolutions, Charlottesville, VA, ³AMPEL BioSolutions, LLC, Charlottesville, VA, ⁴AMPEL BioSolutions and RILITE Research Institute, Charlottesville, VA
Background/Purpose: LN is a serious complication of SLE that affects about 20-40% of all lupus patients and leads to kidney damage, end-stage renal disease, and…
Abstract Number: 1931 • 2019 ACR/ARP Annual Meeting
Comprehensive Characterization of the Immune Infiltrate of Skin Biopsies from Cutaneous Lupus Erythematosus Patients Using Single Cell RNAseq
Agnes Gardet¹, Thomas Carlile ¹, Will Chou ¹, Kejie Li ¹, Alex Pellerin ¹, Ravi Challa ¹, Will Chen ¹, Chao Sun ¹, Nathalie Franchimont ², Victoria Werth ³ and Dania Rabah ¹, ¹Biogen, Cambridge, ²Biogen, Cambridge, MA, ³Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA
Background/Purpose: The immune infiltrate of skin lesions of Cutaneous Lupus Erythematosus (CLE) patients is known to be rich and complex. Single cell RNAseq (scRNAseq) is…
Abstract Number: 1932 • 2019 ACR/ARP Annual Meeting
Genetic Evidence for Recent Positive Selection of the HLA-B*51:01 Allele in the Turkish Population, a Population with a High Prevalence of HLA-B*51-Associated Behçet’s Disease
Elaine Remmers¹, Ahmet Gül ² and Daniel Kastner ¹, ¹National Human Genome Research Institute, Bethesda, MD, ²Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: The Turkish population has one of the highest world-wide prevalence’s of the genetically complex inflammatory Behçet’s disease (BD), estimated as 4 affected per 1000…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].